ISTODAX SIDE EFFECTS
- Generic Name: romidepsin for injection
- Brand Name: Istodax
SIDE EFFECTS
The following adverse reactions are described in more detail in other sections of the prescribing information.
- Myelosuppression
- Infections
- Electrocardiographic Changes
- Tumor Lysis Syndrome
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Cutaneous T-Cell Lymphoma
The safety of ISTODAX was evaluated in 185 patients with CTCL in 2 single arm clinical studies in which patients received a starting dose of 14 mg/m2. The mean duration of treatment in these studies was 5.6 months (range: <1 to 83.4 months).
Common Adverse Reactions
Table 2 summarizes the most frequent adverse reactions (>20%) regardless of causality using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 3.0). Due to methodological differences between the studies, the AE data are presented separately for Study 1 and Study 2. Adverse reactions are ranked by their incidence in Study 1. Laboratory abnormalities commonly reported (>20%) as adverse reactions are included in Table 1.
Table 1. Adverse Reactions Occurring in >20% of Patients in Either CTCL Study (N=185)
Adverse Reactions n (%) | Study 1 (n=102) |
Study 2 (n=83) |
||
All grades | Grade 3 or 4 | All grades | Grade 3 or 4 | |
Any adverse reactions | 99 (97) | 36 (35) | 83 (100) | 68 (82) |
Nausea | 57 (56) | 3 (3) | 71 (86) | 5 (6) |
Asthenia/Fatigue | 54 (53) | 8 (8) | 64 (77) | 12 (14) |
Infections | 47 (46) | 11 (11) | 45 (54) | 27 (33) |
Vomiting | 35 (34) | 1 (<1) | 43 (52) | 8 (10) |
Anorexia | 23 (23) | 1 (<1) | 45 (54) | 3 (4) |
Hypomagnesemia | 22 (22) | 1 (<1) | 23 (28) | 0 |
Diarrhea | 20 (20) | 1 (<1) | 22 (27) | 1 (1) |
Pyrexia | 20 (20) | 4 (4) | 19 (23) | 1 (1) |
Anemia | 19 (19) | 3 (3) | 60 (72) | 13 (16) |
Thrombocytopenia | 17 (17) | 0 | 54 (65) | 12 (14) |
Dysgeusia | 15 (15) | 0 | 33 (40) | 0 |
Constipation | 12 (12) | 2 (2) | 32 (39) | 1 (1) |
Neutropenia | 11 (11) | 4 (4) | 47 (57) | 22 (27) |
Hypotension | 7 (7) | 3 (3) | 19 (23) | 3 (4) |
Pruritus | 7 (7) | 0 | 26 (31) | 5 (6) |
Hypokalemia | 6 (6) | 0 | 17 (20) | 2 (2) |
Dermatitis/Exfoliative dermatitis | 4 (4) | 1 (<1) | 22 (27) | 7 (8) |
Hypocalcemia | 4 (4) | 0 | 43 (52) | 5 (6) |
Leukopenia | 4 (4) | 0 | 38 (46) | 18 (22) |
Lymphopenia | 4 (4) | 0 | 47 (57) | 31 (37) |
Alanine aminotransferase increased | 3 (3) | 0 | 18 (22) | 2 (2) |
Aspartate aminotransferase increased | 3 (3) | 0 | 23 (28) | 3 (4) |
Hypoalbuminemia | 3 (3) | 1 (<1) | 40 (48) | 3 (4) |
Electrocardiogram ST-T wave changes | 2 (2) | 0 | 52 (63) | 0 |
Hyperglycemia | 2 (2) | 2 (2) | 42 (51) | 1 (1) |
Hyponatremia | 1 (<1) | 1 (<1) | 17 (20) | 2 (2) |
Hypermagnesemia | 0 | 0 | 22 (27) | 7 (8) |
Hypophosphatemia | 0 | 0 | 22 (27) | 8 (10) |
Hyperuricemia | 0 | 0 | 27 (33) | 7 (8) |
Serious Adverse Reactions
Infections were the most common type of SAE reported in both studies with 8 patients (8%) in Study 1 and 26 patients (31%) in Study 2 experiencing a serious infection. Serious adverse reactions reported in >2% of patients in Study 1 were sepsis and pyrexia (3%). In Study 2, serious adverse reactions in >2% of patients were fatigue (7%), supraventricular arrhythmia, central line infection, neutropenia (6%), hypotension, hyperuricemia, edema (5%), ventricular arrhythmia, thrombocytopenia, nausea, leukopenia, dehydration, pyrexia, aspartate aminotransferase increased, sepsis, catheter related infection, hypophosphatemia and dyspnea (4%).
There were eight deaths not due to disease progression. In Study 1, there were two deaths: one due to cardiopulmonary failure and one due to acute renal failure. There were six deaths in Study 2: four due to infection and one each due to myocardial ischemia and acute respiratory distress syndrome.
Discontinuations
Discontinuation due to an adverse event occurred in 21% of patients in Study 1 and 11% in Study 2. Discontinuations occurring in at least 2% of patients in either study included infection, fatigue, dyspnea, QT prolongation, and hypomagnesemia.
Peripheral T-Cell Lymphoma
The safety of ISTODAX was evaluated in 178 patients with PTCL in a sponsor-conducted pivotal study (Study 3) and a secondary NCI-sponsored study (Study 4) in which patients received a starting dose of 14 mg/m2. The mean duration of treatment and number of cycles were 5.6 months and 6 cycles in Study 3 and 9.6 months and 8 cycles in Study 4.
Common Adverse Reactions
Table 3 summarizes the most frequent adverse reactions (≥10%) regardless of causality, using the NCI-CTCAE, Version 3.0. The AE data are presented separately for Study 3 and Study 4. Laboratory abnormalities commonly reported (≥10%) as adverse reactions are included in Table 2.
Table 2. Adverse Reactions Occurring in ≥10% of Patients with PTCL in Study 3 and Corresponding Incidence in Study 4 (N=178)
Adverse Reactions n (%) | Study 3 (N=131) |
Study 4 (N=47) |
||
All grades | Grade 3 or 4 | All grades | Grade 3 or 4 | |
Any adverse reactions | 128 (97) | 88 (67) | 47 (100) | 40 (85) |
Gastrointestinal disorders | ||||
Nausea | 77 (59) | 3 (2) | 35 (75) | 3 (6) |
Vomiting | 51 (39) | 6 (5) | 19 (40) | 4 (9) |
Diarrhea | 47 (36) | 3 (2) | 17 (36) | 1 (2) |
Constipation | 39 (30) | 1 (<1) | 19 (40) | 1 (2) |
Abdominal pain | 18 (14) | 3 (2) | 6 (13) | 1 (2) |
Stomatitis | 14 (11) | 0 | 3 (6) | 0 |
General disorders and administration site conditions | ||||
Asthenia/Fatigue | 72 (55) | 11 (8) | 36 (77) | 9 (19) |
Pyrexia | 46 (35) | 8 (6) | 22 (47) | 8 (17) |
Chills | 14 (11) | 1 (<1) | 8 (17) | 0 |
Edema peripheral | 13 (10) | 1 (<1) | 3 (6) | 0 |
Blood and lymphatic system disorders | ||||
Thrombocytopenia | 53 (41) | 32 (24) | 34 (72) | 17 (36) |
Neutropenia | 39 (30) | 26 (20) | 31 (66) | 22 (47) |
Anemia | 33 (25) | 14 (11) | 29 (62) | 13 (28) |
Leukopenia | 16 (12) | 8 (6) | 26 (55) | 21 (45) |
Metabolism and nutrition disorders | ||||
Anorexia | 37 (28) | 2 (2) | 21 (45) | 1 (2) |
Hypokalemia | 14 (11) | 3 (2) | 8 (17) | 1 (2) |
Nervous system disorders | ||||
Dysgeusia | 27 (21) | 0 | 13 (28) | 0 |
Headache | 19 (15) | 0 | 16 (34) | 1 (2) |
Respiratory, thoracic and mediastinal disorders | ||||
Cough | 23 (18) | 0 | 10 (21) | 0 |
Dyspnea | 17 (13) | 3 (2) | 10 (21) | 2 (4) |
Investigations | ||||
Weight decreased | 14 (11) | 0 | 7 (15) | 0 |
Cardiac disorders | ||||
Tachycardia | 13 (10) | 0 | 0 | 0 |
Serious Adverse Reactions
Infections were the most common type of SAE reported. In Study 3, twenty-six patients (20%) experienced a serious infection, including 6 patients (5%) with serious treatment-related infections. In Study 4, eleven patients (23%) experienced a serious infection, including 8 patients (17%) with serious treatment-related infections. Serious adverse reactions reported in ≥2% of patients in Study 3 were pyrexia (8%), pneumonia, sepsis, vomiting (5%), cellulitis, deep vein thrombosis, (4%), febrile neutropenia, abdominal pain (3%), chest pain, neutropenia, pulmonary embolism, dyspnea, and dehydration (2%). In Study 4, serious adverse reactions in ≥2 patients were pyrexia (17%), aspartate aminotransferase increased, hypotension (13%), anemia, thrombocytopenia, alanine aminotransferase increased (11%), infection, dehydration, dyspnea (9%), lymphopenia, neutropenia, hyperbilirubinemia, hypocalcemia, hypoxia (6%), febrile neutropenia, leukopenia, ventricular arrhythmia, vomiting, hypersensitivity, catheter related infection, hyperuricemia, hypoalbuminemia, syncope, pneumonitis, packed red blood cell transfusion, and platelet transfusion (4%).
Reactivation of hepatitis B virus infection has occurred in 1% of patients with PTCL in clinical trials in Western populations enrolled in Study 3 and Study 4.
Deaths due to all causes within 30 days of the last dose of ISTODAX occurred in 7% of patients in Study 3 and 17% of patients in Study 4. In Study 3, there were 5 deaths unrelated to disease progression that were due to infections, including multi-organ failure/sepsis, pneumonia, septic shock, candida sepsis, and sepsis/cardiogenic shock. In Study 4, there were 3 deaths unrelated to disease progression that were due to sepsis, aspartate aminotransferase elevation in the setting of Epstein Barr virus reactivation, and death of unknown cause.
Discontinuations
Discontinuation due to an adverse event occurred in 19% of patients in Study 3 and in 28% of patients in Study 4. In Study 3, thrombocytopenia and pneumonia were the only events leading to treatment discontinuation in at least 2% of patients. In Study 4, events leading to treatment discontinuation in ≥2 patients were thrombocytopenia (11%), anemia, infection, and alanine aminotransferase increased (4%).